AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 APR 18 - (NewsRx.com & NewsRx.net) -- Ciphergen Biosystems, Inc., (CIPH) confirmed that the ovarian cancer detection study was conducted using Ciphergen's ProteinChip Biology System to discover and assay the patterns of proteins utilized in the study. The results were published in Lancet (Feb. 2002).
Undertaken by the U.S. National Cancer Institute and the U.S. Food and Drug Administration, this groundbreaking study discovered protein patterns found in the serum of 50 ovarian cancer patients that distinguished them from 50 women without the disease. These patterns were then used to screen another 116 serum samples, 50 from ovarian cancer patients and 66 from healthy women or women with nonmalignant disease. Using these protein patterns, all 50 of the cancer patients were correctly classified, including 18 with early stage cancer, and 63 of the 66 women without cancer were correctly classified yielding a sensitivity of 100%, ...
Source: HighBeam Research, Ciphergen confirms use of its ProteinChip system.(Brief Article)